Replies to post #319614 on Option Millionaires

[jimmybob]

JPMorgan still sees long road to recovery for Valeant
JPMorgan analyst Chris Schott attributes Valeant Pharmaceuticals' sales and EBITDA beat in Q3 to strong Xifaxan sales and lower than expected operating expenses. Today's results "clearly showed positive core product trends," but the company continues to have a "long road to recovery," Schott tells investors in a research note. He keeps a Neutral rating on Valeant shares. The stock in late morning trading is up 15%, or $1.80, to $13.84